Skip to main content
Signal8

GILEAD SCIENCES, INC. (GILD) Form 8-K — Oct 29, 2026

$GILDForm 8-KItems 2.02, 9.01Filed Oct 29, 2026, 4:03 PM ET0000882095-26-000037Original filing

Gilead reported strong Q3 2026 results, with total product sales up 13% to $8.3 billion and product sales excluding Veklury up 16% to $8.2 billion — its strongest base business growth in more than a decade, led by 18% HIV growth and a near-doubling of HIV prevention sales. Non-GAAP diluted EPS was $2.55 versus $2.47 a year ago, while GAAP EPS fell to $1.94 from $2.43 due to equity securities losses and higher operating expenses and taxes. The company raised full-year 2026 product sales guidance to $31.0-31.3 billion, a cumulative $1.6 billion increase since the start of 2026.

Key figures

Eps
1.94
Revenue
8300000000
Guidance
FY2026 product sales $31.0-31.3B (raised from $30.1-30.4B); non-GAAP diluted loss per share $(1.20)-$(0.85), including ~$9.88 of IPR&D charges from $12.4B in Arcellx, Tubulis, Ouro Medicines and PepStar transactions
Net Income
2429000000
Revenue Yoy
7% total revenues; product sales +13%
Total Assets
51408000000
Cash Position
6437000000
Shares Outstanding
1241000000
Hiv Sales
6249000000
Hiv Growth
18%
Descovy Sales
1046000000
Veklury Sales
86000000
Biktarvy Sales
4059000000
Trodelvy Sales
506000000
Free Cash Flow Q3
4798000000
Non Gaa PDiluted EPS
2.55
Operating Cash Flow Q3
5035000000
Product Gross Margin GAAP
81.0%
Non Gaa PDiluted EPS prior
2.47
Quarterly Dividend Per Share
0.82

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.